The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a loss of -89.31%.However, over the last six months, we can see a weaker performance of 60.22%. Over the last 30 days, the price of RNAZ has fallen by 69.06%. And in the last five days, it has surged by 3.78%.
TransCode Therapeutics Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $20.69 on 10/24/23 and the lowest value was $0.22 on 08/14/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
52-week price history of RNAZ Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. TransCode Therapeutics Inc’s current trading price is -96.59% away from its 52-week high, while its distance from the 52-week low is 226.30%. The stock’s price range during this period has varied between$0.22 and $20.69. The TransCode Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.91 million for the day, a figure considerably lower than their average daily volume of 2.18 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
TransCode Therapeutics Inc (RNAZ) has experienced a quarterly rise of 133.61% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 12.17M and boasts a workforce of 10 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.6045, with a change in price of -1.0850. Similarly, TransCode Therapeutics Inc recorded 1,542,217 in trading volume during the last 100 days, posting a change of -61.13%.
RNAZ’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for RNAZ stands at 0.17. Similarly, the long-term debt-to-equity ratio is also 0.00.
RNAZ Stock Stochastic Average
TransCode Therapeutics Inc’s raw stochastic average for the past 50 days is presently 81.16%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 72.77%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 62.75% and 61.85%, respectively.
